Diagnostic Criteria for Post-Molar GTN After Complete Mole
Post-molar gestational trophoblastic neoplasia (GTN) is diagnosed after complete mole evacuation when hCG levels plateau over 4 consecutive values spanning 3 weeks, rise by >10% over 3 consecutive weekly measurements spanning at least 2 weeks, or persist elevated for 6 months or more after evacuation 1, 2.
FIGO 2000 Diagnostic Criteria
The diagnosis is made through hCG surveillance using the following specific thresholds 1, 2, 3:
- hCG plateau: 4 consecutive plateaued values over a 3-week period (measured weekly)
- hCG rise: >10% increase over 3 consecutive values spanning at least 2 weeks (measured weekly)
- Persistent elevation: hCG remains elevated 6 months or more after molar evacuation
Note that the 6-month persistence criterion is no longer used by many expert centers 3, as most cases meeting this threshold would have already met one of the first two criteria.
Monitoring Protocol After Complete Mole
Following D&C for complete mole 1, 2:
- Measure serum hCG at least every 1-2 weeks until normalization
- Normalization is defined as 3 consecutive normal hCG assays
- After normalization, continue monthly hCG monitoring for 6 months (though risk of recurrence after normalization is <1%)
- Use the same hCG assay type throughout monitoring, preferably as advised by a GTD reference center
Key Clinical Pitfalls
Patients who normalize hCG beyond 56 days post-evacuation have a 3.8-fold higher risk of developing post-molar GTN 2, warranting closer surveillance.
Do not confuse persistent low-level hCG with GTN 1. If hCG remains persistently low without meeting plateau/rise criteria:
- Check urine hCG—if negative with positive serum, suspect false-positive from assay interference (e.g., human antimouse antibodies)
- Exclude exogenous hCG use
- Consult reference laboratory for specialized testing
Initial Assessment When GTN is Diagnosed
Once diagnostic criteria are met 1, 2:
- Doppler pelvic ultrasound: Confirm absence of new pregnancy, measure uterine size, assess tumor volume and vascularity
- Chest X-ray: Screen for pulmonary metastases
- No further imaging needed if chest X-ray is negative before treatment
- If pulmonary metastases present: Add chest/abdominal/pelvic CT and brain MRI
Do not biopsy visible lower genital tract lesions due to severe hemorrhage risk 2.
Alternative to Immediate Chemotherapy
Repeat D&C can be considered for persistent post-molar GTN 2, particularly in patients with:
- Localized uterine disease on imaging
- Lower hCG levels (urinary hCG <1,500 IU/L associated with better outcomes)
- Desire to avoid chemotherapy
In one large series, 68% of patients required no chemotherapy after second curettage 2. However, chemotherapy is more likely needed if histology confirms persistent trophoblastic disease or hCG levels are markedly elevated.
Prognostic Indicators
The presence of atypical extra-villous trophoblast foci in the original mole specimen predicts more aggressive disease 4:
- 68% of post-molar GTN cases have these foci
- Associated with higher FIGO scores ≥6
- More frequent pulmonary metastases (18.4% vs 5.6%)
- All patients requiring multi-agent chemotherapy had atypical foci